← IQVIA HOLDINGS INC. (IQV) — catalysts, pipeline & price
Catalyst Dossier · compiled by CeliA 🧫
IQVIA HOLDINGS INC. (IQV)
Services-Commercial Physical & Biological Research · market cap $45.3B · as of 2026-07-09
Research and calibrated estimates, not financial advice — verify before acting.
Next catalyst
2026-10-27 (est.)
Earnings
Pipeline
20
programs
Upcoming events
5
next 90d+
Dossier
Ready
cached
IQVIA Holdings (IQV) is a global contract research organization (CRO) and health information technology company with $16.3B in 2025 revenue and ~93,000 employees, serving pharma, biotech, and medical device clients. The company carries a heavy net debt load of $13.9B against $1.9B in cash. The immediate catalyst is a Q2 2026 earnings release on July 28, rated modest importance (5/10).
The catalyst path
- 2026-10-27 (est.)Earningsimp 5/10
- 2026-11-05 (est.)Phase 2 · Bedaquiline, pretomanid and TBD09imp 7/10
- 2026-12-26 (est.)Phase 3 · Oregovomabimp 9/10
- 2027-01-30 (est.)Phase 2 · Ixovex-1imp 7/10
- 2027-02-15 (est.)Phase 2 · ER004imp 7/10
Pipeline
| Asset | Phase | Indication |
|---|---|---|
| Oregovomab | Phase 3 | Carcinoma, Ovarian Epithelial |
| Futibatinib | Phase 2 | Advanced Solid Tumor |
| Humira 40 MG in Prefilled Syringe | Phase 3 | Moderate Chronic Plaque Psoriasis |
| Namilumab | Phase 2 | Axial Spondyloarthritis |
| GSK3196165 (Otilimab) | Phase 3 | Arthritis, Rheumatoid |
| FP-101 | Phase 2 | Hot Flashes |
| Olokizumab 64 mg SC q4w | Phase 3 | Rheumatoid Arthritis |
| Recombinant human alpha galactosidase A (agalsidase beta) | Phase 3 | Fabry Disease |
| Benralizumab | Phase 3 | Severe Uncontrolled Asthma |
| Propagermanium | Phase 2 | Focal Segmental Glomerulosclerosis |
| GSK3511294 (Depemokimab) | Phase 3 | Asthma |
| BB2603-1 | Phase 2 | Distal Subungual Onychomycosis |
| Nirsevimab | Phase 2 | RSV Infection |
| Belantamab mafodotin | Phase 2 | Multiple Myeloma |
| Ixovex-1 | Phase 2 | Solid Tumor |
| Etripamil NS | Phase 3 | Paroxysmal Supraventricular Tachycardia |
| ER004 | Phase 2 | X-Linked Hypohidrotic Ectodermal Dysplasia (XLHED) |
| HBI-8000 | Phase 2 | Adult T-Cell Lymphoma (ATL) |
| Efgartigimod | Phase 2 | Primary Sjögren's Syndrome |
| Tapinarof | Phase 3 | Plaque Psoriasis |
Price & technical context
3-month
+25.9%
6-month
+51.2%
12-month
+37.3%
52-wk range
$156.66–$275.02
vs 50-day MA
+3.1%
vs 200-day MA
+26.8%
Realized vol
40.1%
Max drawdown
-44.8%
Daily closes through 2026-10-01. Realized vol annualized; max drawdown over ~2 years.
The full dossier is a Pro feature
Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.
Sources & data
- SEC filings — EDGAR filings for IQV (10-K, 10-Q, S-3, 13D/G, Form 4)
- Clinical trials — 20 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
- Market & financial data — SEC EDGAR (XBRL filings, Form 4), Yahoo Finance, Nasdaq — prices, statements, key metrics, insider & institutional filings.
- Regulatory — openFDA, FDA advisory & PDUFA calendars.
Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.
Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, market-data providers). Compiled by CeliA. Not financial advice.